APA (7th ed.) Citation

M, H., S, K., MA, F., R, B., MA, D., A, D., . . . RN, A. (2025). Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. Oncoimmunology, 14(1), 2546402. https://doi.org/10.1080/2162402X.2025.2546402

Chicago Style (17th ed.) Citation

M, Hasanov, et al. "Lymphodepletion, Tumor-infiltrating Lymphocytes, and High Versus Low Dose IL-2 Followed by Pembrolizumab in Patients with Metastatic Melanoma." Oncoimmunology 14, no. 1 (2025): 2546402. https://doi.org/10.1080/2162402X.2025.2546402.

MLA (9th ed.) Citation

M, Hasanov, et al. "Lymphodepletion, Tumor-infiltrating Lymphocytes, and High Versus Low Dose IL-2 Followed by Pembrolizumab in Patients with Metastatic Melanoma." Oncoimmunology, vol. 14, no. 1, 2025, p. 2546402, https://doi.org/10.1080/2162402X.2025.2546402.